Glutathione

Structure and Biological Role

Glutathione (GSH) is a tripeptide composed of γ-glutamyl-L-cysteinyl-glycine. Its unusual gamma peptide bond — between the side-chain carboxyl of glutamate and the amino group of cysteine — distinguishes it from standard alpha-peptide biochemistry and protects it from conventional aminopeptidase degradation. Glutathione was first isolated by Joseph de Rey-Pailhade in 1888 and fully characterized structurally by Frederick Gowland Hopkins in the 1920s. It is synthesized intracellularly by glutamate-cysteine ligase and glutathione synthetase in essentially every tissue.

GSH is the body's most abundant non-protein thiol and the central small-molecule antioxidant in the mammalian cell. Intracellular concentrations typically range from 1–10 mM, dwarfing most vitamin-based antioxidants by two to three orders of magnitude.

Mechanism of Action

Glutathione performs several related redox functions:

• Direct reactive oxygen species (ROS) neutralization. The reactive cysteine thiol reduces peroxides and free radicals; two GSH molecules oxidize to form a disulfide-linked dimer (GSSG), which is recycled back to GSH by glutathione reductase at NADPH's expense.
• Cofactor for glutathione peroxidases. These selenium-containing enzymes are the principal defense against lipid hydroperoxides and hydrogen peroxide in most cell types.
• Phase II detoxification. Glutathione S-transferases conjugate GSH to electrophilic toxins, drugs, and carcinogens, tagging them for biliary or renal excretion. This is the pathway that rescues the liver from acetaminophen overdose via N-acetylcysteine repletion.
• Protein thiol regulation. GSH maintains cysteine residues on hundreds of proteins in their reduced, functional state.

Evidence for Supplementation

Oral glutathione supplementation has a long-standing bioavailability problem — the tripeptide is largely hydrolyzed in the gut. A 2014 trial by Richie and colleagues found that high-dose oral GSH (1000 mg/day for six months) did modestly raise tissue GSH markers, partially revising earlier pessimism, but the effect size is small. Liposomal, sublingual, and acetylated (S-acetyl glutathione) formulations claim improved absorption, with variable supporting evidence.

Intravenous glutathione is widely used in Parkinson's research, skin-lightening clinics (particularly in Asia), and general wellness IV programs. A 2015 double-blind IV trial in Parkinson's patients found no significant benefit over placebo on UPDRS scores, tempering earlier open-label enthusiasm. Skin-lightening use — driven by GSH's inhibition of tyrosinase — has some clinical data but also a substantial FDA warning regarding compounded IV and injectable products.

Clinical and Regulatory Status

Glutathione itself is not an FDA-approved drug for any indication. It is sold as an oral dietary supplement in the U.S. without restriction. Injectable and IV forms sold through compounding pharmacies have been the subject of repeated FDA cautions regarding sterility, contamination, and unapproved off-label marketing for skin-lightening.

N-acetylcysteine (NAC) — a GSH precursor — is often more effective than GSH itself for raising intracellular glutathione, because cysteine availability is the rate-limiting substrate in GSH synthesis. NAC is FDA-approved for acetaminophen overdose and mucolytic use.

Practical Considerations

Common supplement doses are 250–1000 mg/day oral GSH (ideally liposomal or S-acetyl forms), or 600–1800 mg/day NAC as a precursor. IV protocols in wellness settings typically use 600–2400 mg of GSH per infusion, a dosing range inherited from Parkinson's research with no equivalent validation for healthy-adult use.

Safety Profile

Oral glutathione is extremely well tolerated; occasional gastrointestinal upset is the main reported side effect. IV administration carries the usual infusion-related risks plus specific concerns around compounded product quality. Rare serious adverse events — including Stevens-Johnson syndrome — have been reported with compounded injectable GSH in the skin-lightening context, which is the proximate cause of FDA warnings.

Bottom Line

Glutathione is genuinely important biology and a well-established research tool, but the case for supplementing it — rather than supporting endogenous synthesis via NAC, sleep, and selenium adequacy — is weaker than marketing suggests. It belongs in this library as the tripeptide foundation of cellular redox defense, not as a high-impact wellness intervention. Our biological age article covers where oxidative stress sits within modern aging biomarkers.